Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Prevalence of HIV in patients with malignancy and of malignancy in HIV patients in a tertiary care center from North India.

Sinha S, Agarwal A, Gupta K, Mandal D, Jain M, Detels R, Nandy K, DeVos MA, Sharma SK, Manoharan N, Julka PK, Rath GK, Ambinder RF, Mitsuyasu RT.

Curr HIV Res. 2018 Oct 18. doi: 10.2174/1570162X16666181018161616. [Epub ahead of print]

PMID:
30338741
2.

A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men.

Ellsworth GB, Lensing SY, Ogilvie CB, Lee JY, Goldstone SE, Berry-Lawhorn JM, Jay N, Stier EA, Logan JS, Einstein MH, Saah A, Mitsuyasu RT, Aboulafia D, Palefsky JM, Wilkin TJ.

Papillomavirus Res. 2018 May 26;6:11-14. doi: 10.1016/j.pvr.2018.05.001. [Epub ahead of print] No abstract available.

3.

Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy.

Lee JY, Dhakal I, Casper C, Noy A, Palefsky JM, Haigentz M, Krown SE, Ambinder RF, Mitsuyasu RT.

J Cancer Epidemiol. 2016;2016:2138259. Epub 2016 Nov 2.

4.

Clinical and scientific challenges in HIV-associated malignancies.

Polizzotto MN, Mitsuyasu RT.

Curr Opin HIV AIDS. 2017 Jan;12(1):1-5. No abstract available.

5.

HIV and cancer registry linkage identifies a substantial burden of cancers in persons with HIV in India.

Godbole SV, Nandy K, Gauniyal M, Nalawade P, Sane S, Koyande S, Toyama J, Hegde A, Virgo P, Bhatia K, Paranjape RS, Risbud AR, Mbulaiteye SM, Mitsuyasu RT.

Medicine (Baltimore). 2016 Sep;95(37):e4850. doi: 10.1097/MD.0000000000004850.

6.

Individual-Level, Partnership-Level, and Sexual Event-Level Predictors of Condom Use During Receptive Anal Intercourse Among HIV-Negative Men Who Have Sex with Men in Los Angeles.

Pines HA, Gorbach PM, Weiss RE, Reback CJ, Landovitz RJ, Mutchler MG, Mitsuyasu RT.

AIDS Behav. 2016 Jun;20(6):1315-26. doi: 10.1007/s10461-015-1218-4.

7.

Non-AIDS-defining cancers.

Mitsuyasu RT.

Top Antivir Med. 2014 Jun-Jul;22(3):660-5. Review.

8.

Stage-stratified approach to AIDS-related Kaposi's sarcoma: implications for resource-limited environments.

Krown SE, Borok MZ, Campbell TB, Casper C, Dittmer DP, Hosseinipour MC, Mitsuyasu RT, Mosam A, Orem J, Phipps WT.

J Clin Oncol. 2014 Aug 10;32(23):2512-3. doi: 10.1200/JCO.2014.55.8999. Epub 2014 Jul 7. No abstract available.

9.

High-risk human papillomavirus in HIV-infected women undergoing cervical cancer screening in Lilongwe, Malawi: a pilot study.

Reddy D, Njala J, Stocker P, Schooley A, Flores M, Tseng CH, Pfaff C, Jansen P, Mitsuyasu RT, Hoffman RM.

Int J STD AIDS. 2015 May;26(6):379-87. doi: 10.1177/0956462414539149. Epub 2014 Jun 13.

10.

Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy.

Cillo AR, Krishnan S, McMahon DK, Mitsuyasu RT, Para MF, Mellors JW.

PLoS One. 2014 Mar 17;9(3):e92118. doi: 10.1371/journal.pone.0092118. eCollection 2014.

11.

A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.

Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M Jr, Dowlati A, Little RF, Ivy SP, Deeken JF.

Cancer. 2014 Apr 15;120(8):1194-202. doi: 10.1002/cncr.28554. Epub 2014 Jan 28.

12.

High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine.

Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry MJ, Jay N, Aboulafia DM, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM.

HIV Clin Trials. 2013 Mar-Apr;14(2):75-9. doi: 10.1310/hct1402-75.

13.

Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma.

Cillo AR, Krishnan A, Mitsuyasu RT, McMahon DK, Li S, Rossi JJ, Zaia JA, Mellors JW.

J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):438-41. doi: 10.1097/QAI.0b013e31828e6163.

14.

Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment.

Sinha S, Shekhar RC, Singh G, Shah N, Ahmad H, Kumar N, Sharma SK, Samantaray JC, Ranjan S, Ekka M, Sreenivas V, Mitsuyasu RT.

BMC Infect Dis. 2012 Jul 31;12:168.

15.

Prevalence of HIV drug resistance mutation in the northern Indian population after failure of the first line antiretroviral therapy.

Sinha S, Shekhar RC, Ahmad H, Kumar N, Samantaray JC, Sreenivas V, Khan NH, Mitsuyasu RT.

Curr HIV Res. 2012 Sep;10(6):532-8.

PMID:
22716105
16.

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.

Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, June CH.

Sci Transl Med. 2012 May 2;4(132):132ra53. doi: 10.1126/scitranslmed.3003761.

17.

Meeting the challenge of hematologic malignancies in sub-Saharan Africa.

Gopal S, Wood WA, Lee SJ, Shea TC, Naresh KN, Kazembe PN, Casper C, Hesseling PB, Mitsuyasu RT.

Blood. 2012 May 31;119(22):5078-87. doi: 10.1182/blood-2012-02-387092. Epub 2012 Mar 28. Review.

18.

Phase I/II Clinical Trials Using Gene-Modified Adult Hematopoietic Stem Cells for HIV: Lessons Learnt.

Mitsuyasu RT, Zack JA, Macpherson JL, Symonds GP.

Stem Cells Int. 2011;2011:393698. doi: 10.4061/2011/393698. Epub 2011 Jun 13.

19.

Pilot assessment of HIV gene therapy-hematopoietic stem cell clinical trial acceptability among minority patients and their advisors.

King WD, Wyatt GE, Liu H, Williams JK, DiNardo AD, Mitsuyasu RT.

J Natl Med Assoc. 2010 Dec;102(12):1123-8.

PMID:
21287892
20.

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men.

Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM.

J Infect Dis. 2010 Oct 15;202(8):1246-53. doi: 10.1086/656320.

21.

HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma.

Yu JJ, Fu P, Pink JJ, Dawson D, Wasman J, Orem J, Mwanda WO, Zhu H, Liang X, Guo Y, Petros WP, Mitsuyasu RT, Wabinga H, Remick SC.

PLoS One. 2010 May 17;5(5):e10477. doi: 10.1371/journal.pone.0010477.

22.

Leadership in HIV: now more than ever.

Mitsuyasu RT.

Indian J Med Res. 2008 Dec;128(6):681. No abstract available.

PMID:
19246786
23.

Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.

Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari J, Becker S, Thornton L, Akil B, Khanlou H, Finlayson R, McFarlane R, Smith DE, Garsia R, Ma D, Law M, Murray JM, von Kalle C, Ely JA, Patino SM, Knop AE, Wong P, Todd AV, Haughton M, Fuery C, Macpherson JL, Symonds GP, Evans LA, Pond SM, Cooper DA.

Nat Med. 2009 Mar;15(3):285-92. doi: 10.1038/nm.1932. Epub 2009 Feb 15.

24.

Immune reconstitution inflammatory syndrome manifesting as disseminated tuberculosis, deep venous thrombosis, encephalopathy and myelopathy.

Tahir M, Sinha S, Sharma SK, Mitsuyasu RT.

Indian J Chest Dis Allied Sci. 2008 Oct-Dec;50(4):363-4.

PMID:
19035057
25.

Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes.

Fauce SR, Jamieson BD, Chin AC, Mitsuyasu RT, Parish ST, Ng HL, Kitchen CM, Yang OO, Harley CB, Effros RB.

J Immunol. 2008 Nov 15;181(10):7400-6.

26.

Non--AIDS-defining malignancies in HIV.

Mitsuyasu RT.

Top HIV Med. 2008 Oct-Nov;16(4):117-21. Review.

27.

Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy.

Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG, Holodniy M, Lalezari JP, Levy Y, Mitsuyasu RT, Palella FJ, Pollard RB, Rajagopalan P, Saag MS, Salata RA, Sha BE, Choudhri S.

J Interferon Cytokine Res. 2008 Feb;28(2):89-100. doi: 10.1089/jir.2007.0064.

PMID:
18279104
28.

Use of interleukin-2 in immunotherapy of human immunodeficiency virus infection.

Reier A, Mitsuyasu RT.

BioDrugs. 1998 Sep;10(3):215-25.

PMID:
18020597
29.

Quality of life in a clinical trial of highly active antiretroviral therapy alone or with intravenous or subcutaneous interleukin-2 administration.

Martin BK, Wu AW, Gelman R, Mitsuyasu RT; Adult AIDS Clinical Trials Group.

J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):428-33.

PMID:
16280697
30.

Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients.

Amado RG, Mitsuyasu RT, Rosenblatt JD, Ngok FK, Bakker A, Cole S, Chorn N, Lin LS, Bristol G, Boyd MP, MacPherson JL, Fanning GC, Todd AV, Ely JA, Zack JA, Symonds GP.

Hum Gene Ther. 2004 Mar;15(3):251-62.

PMID:
15018734
31.

Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS.

Ngok FK, Mitsuyasu RT, Macpherson JL, Boyd MP, Symonds GP, Amado RG.

Methods Mol Biol. 2004;252:581-98.

PMID:
15017082
32.

AIDS vaccine 2001: looking to the future.

Mitsuyasu RT.

Afr Health Sci. 2001 Dec;1(2):99-105. Review. No abstract available.

33.
34.

Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects.

Anton PA, Mitsuyasu RT, Deeks SG, Scadden DT, Wagner B, Huang C, Macken C, Richman DD, Christopherson C, Borellini F, Lazar R, Hege KM.

AIDS. 2003 Jan 3;17(1):53-63.

PMID:
12478069
35.

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW; AIDS Clinical Trials Group 398 Study Team.

JAMA. 2002 Jul 10;288(2):169-80.

PMID:
12095381
36.

A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.

Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM.

Mol Ther. 2002 Jun;5(6):788-97.

37.

The potential role of interleukin-2 in HIV.

Mitsuyasu RT.

AIDS. 2001 Feb;15 Suppl 2:S22-7. Review.

PMID:
11424973
38.

Immune Reconstitution Strategies in HIV.

Leibowitz MR, Mitsuyasu RT.

Curr Infect Dis Rep. 2001 Jun;3(3):302-308.

PMID:
11384562
39.

Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease.

Emery S, Capra WB, Cooper DA, Mitsuyasu RT, Kovacs JA, Vig P, Smolskis M, Saravolatz LD, Lane HC, Fyfe GA, Curtin PT.

J Infect Dis. 2000 Aug;182(2):428-34. Epub 2000 Jul 28.

PMID:
10915072
40.

Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects.

Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S, Lin AA, Pennathur-Das R, Hege KM.

Blood. 2000 Aug 1;96(3):785-93.

41.

AIDS-related Kaposi's sarcoma: current treatment options, future trends.

Mitsuyasu RT.

Oncology (Williston Park). 2000 Jun;14(6):867-78; discussion 878, 881-3, 887-. Review.

42.

Update on the pathogenesis and treatment of Kaposi sarcoma.

Mitsuyasu RT.

Curr Opin Oncol. 2000 Mar;12(2):174-80. Review.

PMID:
10750730
43.

A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme.

Amado RG, Mitsuyasu RT, Symonds G, Rosenblatt JD, Zack J, Sun LQ, Miller M, Ely J, Gerlach W.

Hum Gene Ther. 1999 Sep 1;10(13):2255-70. No abstract available.

PMID:
10498256
44.

Gene therapy for the treatment of AIDS: animal models and human clinical experience.

Amado RG, Mitsuyasu RT, Zack JA.

Front Biosci. 1999 May 15;4:D468-75. Review.

PMID:
10331991
45.

Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.

Bucy RP, Hockett RD, Derdeyn CA, Saag MS, Squires K, Sillers M, Mitsuyasu RT, Kilby JM.

J Clin Invest. 1999 May 15;103(10):1391-8.

46.

Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection.

Aziz N, Nishanian P, Taylor JM, Mitsuyasu RT, Jacobson JM, Dezube BJ, Lederman MM, Detels R, Fahey JL.

J Infect Dis. 1999 Apr;179(4):843-8.

PMID:
10068579
47.

Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team.

Mitsuyasu RT, Skolnik PR, Cohen SR, Conway B, Gill MJ, Jensen PC, Pulvirenti JJ, Slater LN, Schooley RT, Thompson MA, Torres RA, Tsoukas CM.

AIDS. 1998 Jul 30;12(11):F103-9.

PMID:
9708399
48.

AIDS Clinical Trials Group Study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma.

Gill PS, Mitsuyasu RT, Montgomery T, Huang J, Cabriales S, Testa M, Espina BM, Levine AM, Miles SA.

Cancer J Sci Am. 1997 Sep-Oct;3(5):278-83.

PMID:
9327151
49.

Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection.

Eron JJ Jr, Ashby MA, Giordano MF, Chernow M, Reiter WM, Deeks SG, Lavelle JP, Conant MA, Yangco BG, Pate PG, Torres RA, Mitsuyasu RT, Twaddell T.

Lancet. 1996 Dec 7;348(9041):1547-51.

PMID:
8950881
50.

Chemotherapy of AIDS--related Kaposi's sarcoma.

Lee FC, Mitsuyasu RT.

Hematol Oncol Clin North Am. 1996 Oct;10(5):1051-68. Review.

PMID:
8880196

Supplemental Content

Loading ...
Support Center